In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis (RA). It was found that between 12.5 percent and 20 percent of patients who were given the drug on a daily basis experienced so-called "sustained remission"—a state that is almost like being cured. The results of the study have now been published in top journal The Lancet.
* This article was originally published here
